

Myocarditis Tops List of COVID Vaccine Injuries Among 12- to 17-Year-Olds, VAERS Data Show

By Megan Redshaw Global Research, January 18, 2022 Children's Health Defense 14 January 2022 Region: <u>USA</u> Theme: <u>Science and Medicine</u>

All Global Research articles can be read in 51 languages by activating the "Translate Website" drop down menu on the top banner of our home page (Desktop version).

To receive Global Research's Daily Newsletter (selected articles), <u>click here</u>.

Visit and follow us on Instagram at @globalresearch_crg.

VAERS data released Friday by the Centers for Disease Control and Prevention included a total of 1,033,994 reports of adverse events from all age groups following COVID vaccines, including 21,745 deaths and 170,446 serious injuries between Dec. 14, 2020, and Jan. 7, 2022.

The Centers for Disease Control and Prevention (CDC) today released new data showing a total of <u>1,033,994 reports of adverse events</u> following COVID vaccines were submitted between Dec. 14, 2020, and Jan. 1, 2022, to the Vaccine Adverse Event Reporting System (VAERS). VAERS is the primary government-funded system for reporting adverse vaccine reactions in the U.S.

The data included a total of 21,745 reports of deaths — an increase of 363 over the previous week — and 170,446 reports of serious injuries, including deaths, during the same time period — up 3,840 compared with the previous week.

Excluding "<u>foreign reports</u>" to VAERS, <u>723,042 adverse events</u>, including <u>9,936 deaths</u> and <u>64,406 serious injuries</u>, were reported in the U.S. between Dec. 14, 2020, and Jan. 7, 2022.

<u>Foreign reports</u> are reports foreign subsidiaries send to U.S. vaccine manufacturers. Under U.S. Food and Drug Administration (FDA) regulations, if a manufacturer is notified of a foreign case report that describes an event that is both serious and does not appear on the product's labeling, the manufacturer is required to submit the report to VAERS.

Of the 9,936 U.S. <u>deaths reported</u> as of Jan. 7, 19% occurred within 24 hours of vaccination, 24% occurred within 48 hours of vaccination and 61% occurred in people who experienced an <u>onset of symptoms</u> within 48 hours of being vaccinated.

In the U.S., 516 million COVID vaccine doses had been administered as of Jan. 7, including 303 million doses of Pfizer, 197 million doses of Moderna and 18 million doses of Johnson & Johnson (J&J).

Search Results

From the 1/7/2022 release of VAERS data:

Found 1,033,994 cases where Vaccine is COVID19

Covernment Disclaimer on use of this data

Event Outparte	↑ ↓	
	Count	Percent
Durth	21,745	115
Permanent Disability	97,897	3.675
Office Viet	101,430	15.615
Energency Noon	90	0.01%
Energency Doctor/Room	1(2,)45	10.85%
Hospitalized	718,446	31.125
Hospitalized, Protomped	300	0.00%
Repovered	300,000	25.00
Birth Genet	008	0.00%
Life Threatening	24,790	141
Not Serious	452,559	49.775
TOTAL	t 1.227.906	1 110,751

Every Friday, <u>VAERS</u> publishes vaccine injury reports received as of a specified date. Reports submitted to VAERS require further investigation before a causal relationship can be confirmed. Historically, VAERS has been shown to report only <u>1% of actual vaccine adverse events</u>.

U.S. VAERS data from Dec. 14, 2020, to Jan. 7, 2022, for 5- to 11-year-olds show:

• 6,399 adverse events, including <u>142 rated as serious</u> and <u>3 reported deaths</u>.

The most recent death involves a 7-year-old girl (VAERS I.D. <u>1975356</u>) from Minnesota who died 11 days after receiving her first dose of Pfizer's COVID vaccine when she was found unresponsive by her mother. An autopsy is pending.

- <u>14 reports</u> of myocarditis and pericarditis (heart inflammation).
- <u>22 reports</u> of blood clotting disorders.

U.S. VAERS data from Dec. 14, 2020, to Jan. 7, 2022, for 12- to 17-year-olds show:

• 26,631 adverse events, including 1,530 rated as serious and 35 reported deaths.

The most recent death involves a 15-year-old girl from Minnesota (VAERS I.D. <u>1974744</u>), who died 177 days after receiving her second dose of Pfizer from a pulmonary embolus. An autopsy is pending.

• 62 reports of anaphylaxis among 12- to 17-year-olds where the reaction was life-

threatening, required treatment or resulted in death — with 96% of cases attributed to <u>Pfizer's vaccine</u>.

- <u>589 reports</u> of myocarditis and pericarditis with <u>578 cases</u> attributed to Pfizer's vaccine.
- <u>149 reports</u> of blood clotting disorders, with all cases attributed to Pfizer.

U.S. VAERS data from Dec. 14, 2020, to Jan. 7, 2022, for all age groups combined, show:

- 19% of deaths were related to cardiac disorders.
- 55% of those who died were male, 42% were female and the remaining death reports did not include the gender of the deceased.
- The <u>average age</u> of death was 72.6.
- As of Jan. 7, <u>4,806 pregnant women</u> reported adverse events related to COVID vaccines, including 1,533 reports of <u>miscarriage or premature birth</u>.
- Of the <u>3,419 cases of Bell's Palsy</u> reported, 51% were attributed to <u>Pfizer</u> vaccinations, 41% to <u>Moderna</u> and 8% to J&J.
- 836 reports of <u>Guillain-Barré syndrome</u> (GBS), with 41% of cases <u>attributed to</u> <u>Pfizer</u>, 30% to <u>Moderna</u> and 28% to <u>J&J</u>.
- <u>2,256 reports</u> of anaphylaxis where the reaction was life-threatening, required treatment or resulted in death.
- 12,331 reports of blood clotting disorders in the U.S. Of those, <u>5,457 reports</u> were attributed to Pfizer, <u>4,398 reports</u> to Moderna and <u>2,428 reports</u> to J&J.
- <u>3,688 cases</u> of myocarditis and pericarditis with <u>2,269 cases</u> attributed to Pfizer, <u>1,249 cases</u> to Moderna and <u>158 cases</u> to J&J's COVID vaccine.

26-year-old man dies from myocarditis caused by Pfizer COVID vaccine

A 26-year-old South Dakota man died Nov. 12, 2021, of myocarditis, just four days after receiving a booster dose of Pfizer's COVID vaccine. Joseph Keating had no idea he was experiencing a rare and supposedly "mild" heart problem after the shot.

His only warning signs were fatigue, muscle soreness and an increased heart rate, family members said.

In an exclusive interview Jan. 11 with <u>The Defender</u>, Joseph's father, mother and sister said the CDC had not investigated Joseph's death, nor did the agency contact the pathologist who performed the autopsy or request the documents which confirmed Joseph's death was caused by the Pfizer vaccine.

According to the <u>autopsy report</u> and <u>certificate of death</u>, Joseph died from severe heart damage from "myocarditis in the left ventricle due to the recent Pfizer COVID-19 booster vaccine."

In an exclusive interview with The Defender, Joseph Keating's mother said her son's only warning signs were fatigue, muscle soreness and an increased heart rate, yet an autopsy confirmed he died of myocarditis directly caused by Pfizer's COVID vaccine.<u>https://t.co/Htk7GHXz6o</u>

Robert F. Kennedy Jr (@RobertKennedyJr) January 11, 2022

Supreme Court strikes down OSHA mandate, allows healthcare mandate to proceed

The U.S. Supreme Court on Thursday issued two opinions on the Biden administration's <u>COVID vaccine mandates</u> on whether to stay or to grant temporary injunctions requested by plaintiffs in a <u>number of lawsuits</u> challenging the emergency mandates for millions of Americans.

First, the justices rejected the Biden administration's mandate requiring employees of large businesses to be vaccinated against <u>COVID</u> or undergo weekly testing and wear a mask indoors while working.

The court's conservative majority said the administration overstepped its authority by imposing the Occupational Safety and Health Administration's (OSHA) vaccine-or-test rule on U.S. businesses with at least 100 employees.

In a second ruling, the justices said the mandates for workers in healthcare facilities that receive Medicare or Medicaid funding could stay in place while the lawsuits work their way through the lower courts.

The mandate is estimated to affect 10.3 million healthcare workers in the U.S., but allows for religious and medical exemptions.

Pfizer CEO says 2 shots offer 'very limited protection, if any' against COVID

During an <u>interview</u> on CNBC's "Squawk Box" on Monday, Pfizer CEO Albert Bourla said two doses of Pfizer's COVID vaccine — initially referred to as a full regimen — "offers very limited protection, if any" against the <u>Omicron</u> variant.

When a third, or booster dose, is administered the vaccine offers only "reasonable protection" against hospitalization and death from Omicron and "less protection against infection," Bourla said.

Bourla previously claimed a two-dose regimen was "100% effective."

EU regulators, WHO call for end of boosters

European Union drug regulators on Tuesday warned <u>frequent COVID boosters</u> could risk overloading the immune system and said there are currently no data to support repeated doses.

This comes a month after the regulators <u>said</u> it made sense to "administer COVID-19 vaccine boosters as early as three months after the initial two-shot regimen," amid concerns over the Omicron variant.

The World Health Organization's Technical Advisory Group on COVID-19 Vaccine Composition on Jan. 11 also <u>warned</u>, "a vaccination strategy based on repeated booster doses of the original vaccine composition is unlikely to be appropriate or sustainable."

The group said giving additional doses of already existing vaccines as new strains of the virus emerge is not the best way to fight a pandemic, as currently available COVID vaccines do not prevent infection or transmission and the current composition of COVID vaccines need to be updated.

Djokovic's visa canceled second time over unvaccinated status

Australian authorities today revoked Novak Djokovic's visa due to his unvaccinated status, in the latest twist in the <u>ongoing battle</u> over whether the nine-time Australian Open champion will be allowed to defend his title.

As <u>The Defender reported</u>, Australian Minister Alex Hawke used his ministerial discretion to cancel the No. 1 ranked Tennis player's visa citing "health or good order grounds," just three days before the Australian Open begins and four days after a federal judge ordered Djokovic be released from hotel detention when his visa was revoked the first time.

Djokovic's lawyers are contesting the visa cancellation in court, in an attempt to allow him to play in the prestigious tennis tournament. If unsuccessful, Djokovic will face deportation.

*

Note to readers: Please click the share buttons above or below. Follow us on Instagram, @crg_globalresearch. Forward this article to your email lists. Crosspost on your blog site, internet forums. etc.

Megan Redshaw is a freelance reporter for The Defender. She has a background in political science, a law degree and extensive training in natural health.

Featured image is from CHD

The original source of this article is <u>Children's Health Defense</u> Copyright © <u>Megan Redshaw</u>, <u>Children's Health Defense</u>, 2022

Comment on Global Research Articles on our Facebook page

Become a Member of Global Research

Articles by: Megan Redshaw

Disclaimer: The contents of this article are of sole responsibility of the author(s). The Centre for Research on Globalization will not be responsible for any inaccurate or incorrect statement in this article. The Centre of Research on Globalization grants permission to cross-post Global Research articles on community internet sites as long the source and copyright are acknowledged together with a hyperlink to the original Global Research article. For publication of Global Research articles in print or other forms including commercial internet sites, contact: publications@globalresearch.ca

<u>www.globalresearch.ca</u> contains copyrighted material the use of which has not always been specifically authorized by the copyright owner. We are making such material available to our readers under the provisions of "fair use" in an effort to advance a better understanding of political, economic and social issues. The material on this site is distributed without profit to those who have expressed a prior interest in receiving it for research and educational purposes. If you wish to use copyrighted material for purposes other than "fair use" you must request permission from the copyright owner.

For media inquiries: publications@globalresearch.ca